Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NeOnc Technologies Holdings, Inc. ( (NTHI) ) has issued an update.
On December 15, 2025, NeOnc Technologies Holdings, Inc. reported updated results from its clinical trials evaluating intranasal NEO100 for recurrent WHO Grade III/IV IDH1-mutant astrocytoma patients. Results showed significant advancements, as 24% of trial participants achieved radiographic remission, substantially outperforming typical rates of salvage therapies. Additionally, 44% of patients achieved progression-free survival at six months, and 36% demonstrated durable survival for at least 18 months. These findings point to NEO100’s potential as a transformative CNS-penetrant metabolic therapy with significant survival benefits in heavily pretreated populations, challenging historically palliative approaches. No toxicity concerns were observed, further backing its promise to improve treatment outcomes for CNS cancer patients.
More about NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative therapeutics for central nervous system cancers. Utilizing its proprietary NEO drug development platform, the company has created a portfolio of patented drug candidates and delivery methods, including NEO100 and NEO212, which are in advanced clinical trials and aim to address challenges such as penetrating the blood-brain barrier.
Average Trading Volume: 74,145
Technical Sentiment Signal: Strong Buy
Current Market Cap: $183.8M
Find detailed analytics on NTHI stock on TipRanks’ Stock Analysis page.